Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer | Zendy

AI Assistant Blog Pricing

Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.